期刊
CLINICAL KIDNEY JOURNAL
卷 14, 期 8, 页码 1924-1931出版社
OXFORD UNIV PRESS
DOI: 10.1093/ckj/sfaa237
关键词
excretion; hyperkalemia; Phase 1 study; potassium; sodium; sodium zirconium cyclosilicate
资金
- ZS Pharma, Inc.
The study suggests that sodium zirconium cyclosilicate can effectively reduce serum potassium concentration and urinary potassium excretion, with no significant impact on urinary sodium excretion, and is well tolerated.
Background. Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a potassium (K+) binder for treatment of hyperkalemia in adults. SZC binds K+ in exchange for sodium (Na+) or hydrogen (H+) in the gastrointestinal tract, conveying potential for systemic absorption of Na+. Methods. This single-center Phase 1 study evaluated the effects of SZC on Na+ and K+ excretion in healthy, normokalemic adults. During an initial run-in period (Days 1-2), participants started a high K+/low Na+ diet. After baseline (Days 3-4), SCZ 5 or 10 g once daily (QD) was administered (Days 5-8). The primary endpoint was mean change in urinary Na+ excretion from baseline (Days 3-4) to the treatment period (Days 7-8). Results. Of 32 enrolled participants, 30 entered and completed the study; the first 15 received 5 g and the next 15 received 10 g. Nonsignificant changes from baseline in urinary Na+ excretion were observed with SZC 5 g (mean +/- SD -0.93 +/- 25.85 mmol/24 h) and 10 g (-5.47 +/- 13.90 mmol/24 h). Statistically significant decreases from baseline in urinary K+ excretion (mean +/- SD -21.17 +/- 21.26 mmol/24 h; P = 0.0017) and serum K+ concentration (-0.25 +/- 0.24 mmol/L; P = 0.0014) were observed with the 10-g dose. There were few adverse events and no clinically meaningful changes in vital signs or laboratory safety measures. Conclusions. Treatment with SZC 5 or 10 g QD reduced serum K+ concentration and urinary K+ excretion, with no significant effect on urinary Na+ excretion, and was well tolerated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据